Antiviral PK 2018 – Presentations


Tuesday 22 MayWednesday 23 MayThursday 24 May

TUESDAY, MAY 22, 2018

 Session 1: New technologies and formulations
  Thomas, David 2016 120x160How to End the Global HCV Epidemic - the role of injectables
David Thomas, MD
  koup, richard 2015Clinical Development of Long-Acting Broadly Neutralizing Monoclonal Antibodies: Lessons Learned Thus Far
Richard Koup, MD
  Becker, Stephen 2014Viral Dynamics and the Search for an HIV Cure 
Steven Becker, MD
  Back to top 


 Session 2: Hepatitis related topic
  Burger,David 2018, 120 x 160The use of DAA’s in pregnancy in HCV infected mothers
David Burger, PharmD
  Thomas, David 2016 120x160Clinical case presentation
David Thomas, MD

Cressey, Tim 2017 120x160Tenofovir exposure during pregnancy and postpartum in hepatitis B mono-infected women on TDF monotherapy compared to HIV-infected women on TDF-containing antiretroviral therapy

Tim Cressey, PhD


Intracellular 007-TP Concentrations are Associated with Gradients of Adherence to Ledipasvir/Sofosbuvir

Leah Jimmerson, PhD


A Pharmacometabolomics Approach for Predicting Tenofovir diphosphate (TFV-DP) Concentrations in Dried Blood Spots (DBS)

Mustafa Ibrahim

 Session 3: Round Table discussion: validation of Physiologically based pharmacokinetic (PBPK) modeling 
  Gobburu, Joga 2014_120Application of Physiologically based pharmacokinetic (PBPK) Modelling to Drug Development Decisions
Joga Gobburu, PhD, MBA 
  Yeo, Karen 2018 120 x 160Application of PBPK modelling for assessment of DDI liability in combination therapies
(Not available)

Karen Yeo, PhD
  Zhang, Xinxin 2016_120Physiologically based pharmacokinetic modeling and simulation in drug product development and review 
Xinyuan Zhang, PhD
 Session 4: Towards Precision Medicine 
  Haas_David 2011How/when will pharmacogenomics translate into improved clinical care?
David Haas, MD
  Calcagno, Andrea 120 x 160Last advances in HIV pharmacogenomics 
Andrea Calcagno, MD

SLC22a2 genetic variants and dolutegravir trough concentrations correlate with specific psychiatric symptoms in hiv-positive patients on dolutegravir

Alberto Borghetti, PhD


Age, Inflammation, Blood Brain Barrier Permeability and Single Nucleotide Polymorphisms in Transporters May Influence Cerebrospinal Fluid Antiretrovirals' Concentrations

Andrea Calcagno, MD


Assessment of maternal and fetal dolutegravir exposure by integrating ex vivo placental perfusion data and physiologically-based pharmacokinetic modeling

Jolien Freriksen, MSc


Does hepatic impairment affect the exposure of monoclonal antibodies? 

Qin Sun, PhD


Reduced nevirapine concentrations among HIV-positive women receiving mefloquine for intermittent preventive treatment for malaria control during pregnancy

Richard Haaland


Elvitegravir pharmacokinetics during Pregnancy and Postpartum

Angela Colbers, PhD

 Session 5: HIV related topic
  Di Perri, Giovanni 2016 120x160Clinical Pharmacology of Integrase Inhibitors 
Giovanni di Perri, MD, PhD
  Clinical case presentation 
Marta Boffito, PhD

Pharmacokinetics of Dolutegravir 100 MG once-daily with Rifampicin

Marta Boffito, PhD


Pharmacokinetic and virological efficacy of dolutegravir (50 mg BID) containing regimen in association with rifampin in HIV-infected patients using Dried Blood Spot: ANRS-12313 NAMSAL sub-study in Cameroon

Minh Le


First report of dolutegravir unbound plasma concentrations during pregnancy in HIV-positive women

Pauline Bollen

 Back to top 

THURSDAY, MAY 24, 2018

 Session 6: Drug - Drug interactions related session

Yang, Xinning 2018Update on DDI guidelines of the FDA - in vitro

Xinning Yang, PhD


Reynolds, Kellie 2017Update on DDI guidelines of the FDA - in vivo

Kellie Reynolds, PharmD


Medication safety issues associated with currently used first-line antiretroviral regimens in Uganda

Kay Seden


Intraindividual comparison of efavirenz, atazanavir, or ritonavir plasma pharmacokinetics before and during 21-days of vaginally administered hormone contraception

Kimberly Scarsi, PharmD, MS


Rifabutin (RBT) Decreases Cabotegravir (CAB) Exposure Following Oral Co-administration

Parul Patel, PharmD


Rifabutin PK and Safety among HIV/TB–Coinfected Children Receiving Lopinavir

Holly Rawizza, MD


Clinical Pharmacology of HIV Pre-Exposure Prophylaxis (PrEP) – Where are we now

Craig Hendrix, MD


Comparison of 5 online free access expert databases to check drug-drug interactions between antiretroviral drugs and co-prescribed medications from a French cohort of HIV-infected outpatients. 

Minh Le


Polypharmacy, drug-drug interactions and potentially inappropriate prescribing in elderly patients of the swiss HIV cohort study
(Not available) 

Catia Marzolini, PharmD, PhD


Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics of Etravirine in HIV-positive Children Ages 1-<6 Years

Mustafa Ibrahim


Differential brain tissue penetration of antiretrovirals and fluconazole

Katelyn Pastick

 Back to top